ClinicalTrials.gg
CompletedNCT02894398INGE-BUpdated Mar 13, 2023

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

A Phase 2 interventional study of Palbociclib and Letrozole in Breast Cancer, Hormone Receptor Positive Tumor and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, sponsored by iOMEDICO AG. Completed at 70 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by iOMEDICO AG · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
388
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Enrollment
19th of 111
388 · median 100
Started
2016
with 14 others
Phase 2
62 of 111
8 open now
Registered
43rd of 111
by date

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 19th largest by enrollment, is one of 15 that started in 2016, is one of 62 in phase 2, and was the 43rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and quality of life in women with advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the breast), HR+ / HER2-, who are treated with an aromatase inhibitor or fulvestrant as baseline therapy in combination with palbociclib (Ibrance)

Read the detailed description

This is a prospective, open-label, multi-center, single arm, non-comparative phase II study in women with HR+/HER2- advanced breast cancer receiving palbociclib in addition to an aromatase inhibitor or fulvestrant. The study will take place in Germany (85 study centers).

In total, 360 patients will be enrolled in this study. 6 treatment groups are planned. The study seeks to recruit 60 (58-62) patients per recruitment group. For first-line treatment with palbociclib - and letrozole (Enrollment Group 1), anastrozole (Enrollment Group 2), exemestane (Enrollment Group 3) or fulvestrant (Enrollment Group 4) and 60 (58-62) patients for second- or later-line treatment with palbociclib -and letrozole (Enrollment Group 5) or fulvestrant (Enrollment Group 6). Recruitment will be centrally monitored to allow closure of a respective group as soon as 60 (58-62) patients have been enrolled.

Treatment will be continued until disease progression, intolerable toxicity, death or any other reason. In case a combination partner is discontinued, palbociclib has to be discontinued. In case treatment with palbociclib is stopped, combination partner can be continued according to investigator's discretion. Irrespectively of the combination partner, the discontinuation of palbociclib is defined as end of treatment (EOT) in this study. After EOT the patient enters the follow-up period.

Primary end point is clinical benefit rate 24 weeks after the first study treatment of the patient.

A study independent, decentral, "virtual" biobank will be established. All patients will be asked to give consent for their tumor samples to be used for future investigational research. Study sites will inform the local pathologists about the patient's consent and ask for the tissue sample to be reserved for future analyses. The site is requested to collect contact details of the pathologist storing the tumor sample, the sample's identification number(s), and to document these in the eCRF.

The decision to perform subsequent investigational research studies on collected samples will be based on outcome data from this study or from new scientific findings related to the drug class or disease, as well as reagent and assay availability.

03

Conditions studied

  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Keywords

  • HR+
  • HER2-
  • Locally advanced (inoperable or metastatic) Breast Cancer
  • Palbociclib
  • Aromatase inhibitor or fulvestrant
  • Pre-/perimenopausal receiving LHRH agonist / ovarian ablation
  • Postmenopausal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Personally signed written prior to beginning protocol specific procedures, including expected cooperation of the patient for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements
  2. Women with proven diagnosis of advanced, defined as locally advanced inoperable or , adenocarcinoma of the breast
  3. Hormone-receptor-positive (HR+) disease, defined as estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PgR+)
  4. Human epidermal growth factor receptor 2-negative (-) disease (HER2 neg/+ or HER2++ with CISH/FISH neg.)
  5. Pre-/perimenopausal women receiving concomitant therapy with an luteinizing hormone-releasing hormone (LHRH) agonist / ovarian ablation or status
  6. Age ≥18 years
  7. as per [RECIST] or bone-only disease
  8. Patients scheduled for palliative treatment with an combination partner for first- or
  9. (ECOG) performance status 0-2
  10. Adequate organ and marrow function
  11. Resolution of all acute toxic effects of prior therapy, including radiotherapy Grade \<1 (except toxicities not considered a safety risk for the patient) and recovery from surgical procedures
  12. Fluent in spoken and written German

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any CDK4/6 inhibitor
  2. Prior therapy with the respective endocrine combination partner if last intake \<12 months prior to entering the study
  3. Prior palliative therapy with the respective endocrine combination partner
  4. More than one prior palliative chemotherapy
    1. Known to letrozole, anastrozole, exemestane, fulvestrant or any of their
  5. Current use of food or drugs known to be potent inhibitors or inducers of (refer to Appendix 15.4)
  6. Current use of preparations containing St. John's Wort
  7. Participation in other studies involving drug(s) (Phases I-IV) within 2 weeks before the current study treatment begins
  8. > 480 msec on the screening (using the QTcF formula and/or the QTcB (Bazett) formula); history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes
  9. High cardiovascular risk, including, but not limited to recent myocardial infarction, severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment
  10. Patients with advanced symptomatic, visceral spread, that were at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement)
  11. Diagnosis of any second within the last 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
  12. Known, not-irradiated
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    Palbociclib+AI or Fulvestrant

    Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.

    Drug: Palbociclib · Drug: Letrozole · Drug: Anastrozole · Drug: Exemestane · Drug: Fulvestrant

Interventions

  • Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days. Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons

    Also known as: Ibrance

  • Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake

    Also known as: Femara

  • Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake

    Also known as: Arimidex

  • Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake

    Also known as: Aromasin

  • Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection

    Also known as: Faslodex

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate (CBR)

    CBR is defined as complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.

    Time frame: 24 weeks after first administration of Palbociclib in combination with AI / fulvestrant

Secondary outcomes

  1. Number of participants with Adverse Events as assessed by CTCAE V4.0

    Adverse Events as characterized by type, frequency, severity (as graded by National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] v.4.03), and seriousness

    Time frame: From Date of Signed informed consent until PD, assessed up to 60 months.

  2. Clinical Benefit Rate (CBR)

    CBR is defined as complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.

    Time frame: 48 weeks after first administration of Palbociclib in combination with AI / fulvestrant

  3. Progression-free Survival rate

    Follow up 4 years after LPI

    Time frame: At 48 weeks (all patients) and 2 years (first-line patients only) after first administration of Palbociclib in combination with AI / fulvestrant

  4. Overall Survival rate

    Follow up 4 years after LPI

    Time frame: At 48 weeks after first administration of Palbociclib in combination with AI / fulvestrant and yearly until EOS, assessed up to 60 months.

  5. Time on treatment

    Study treatment will be continued until disease progression, intolerable toxicity, death or any other reason.

    Time frame: From day of first treatment until permanent discontinuation (EOT), assessed up to 60 months.

  6. Dosage

    * starting dose (mg) * adjusted doses (mg)

    Time frame: From day of first treatment until EOT, assessed up to 60 months.

  7. Adminstration schedule

    - dates of administration

    Time frame: From day of first treatment until EOT, assessed up to 60 months.

  8. Health-related quality of life (QoL)

    Health-related QoL will be assessed with the FACT-B (Functional Assessment of Cancer Therapy-Breast) questionnaire

    Time frame: From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.

  9. Health-related fatigue

    Fatigue will be assessed with the BFI (Brief Fatigue Inventory) questionnaire

    Time frame: From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.

  10. Health-related anxiety and depression

    Depression and anxiety will be assessed with the HADS-D (Hospital Anxiety and Depression Scale) questionnaire

    Time frame: From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.

  11. Physician's assessment of patient's overall health status and change in health status compared to previous visit

    Assessed by 2 items at each cycle/at scheduled patient visit

    Time frame: From Screening until disease progression or start of next anti-cancer therapy, assessed up to 60 months.

07

Study locations

70 sites
  • Research Site
    Aachen, Germany
  • Research Site
    Aschaffenburg, Germany
  • Augsburg, Germany
  • Research Site
    Baden-Baden, Germany
  • Research Site
    Berlin, Germany
  • Bochum, Germany
  • Bonn, Germany
  • Research Site
    Bottrop, Germany
  • Bremerhaven, Germany
  • Research Site
    Celle, Germany
  • Dessau, Germany
  • Research Site
    Donauwörth, Germany
  • Research Site
    Dortmund, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Esslingen, Germany
  • Research Site
    Frankfurt, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Gerlingen, Germany
  • Goslar, Germany
  • Greifswald, Germany
  • Research Site
    Göttingen, Germany
  • Göttingen, Germany
  • Güstrow, Germany
  • Research Site
    Gütersloh, Germany
  • Research Site
    Halle, Germany
  • Research Site
    Hamburg, Germany
  • Homburg, Germany
  • Ilsede, Germany
  • Kaiserslautern, Germany
  • Research Site
    Karlsruhe, Germany
  • Research Site
    Kassel, Germany
  • Research Site
    Krefeld, Germany
  • Research Site
    Langen, Germany
  • Research Site
    Leer, Germany
  • Luneburg, Germany
  • Lörrach, Germany
  • Lübeck, Germany
  • Mannheim, Germany
  • Minden, Germany
  • Research Site
    Mönchengladbach, Germany
  • Research Site
    Mühlhausen, Germany
  • Mülheim, Germany
  • Research Site
    München, Germany
  • München, Germany
  • Research Site
    Münster, Germany
  • Neumünster, Germany
  • Neuruppin, Germany
  • Offenburg, Germany
  • Oldenburg, Germany
  • Passau, Germany
  • Potsdam, Germany
  • Research Site
    Recklinghausen, Germany
  • Research Site
    Regensburg, Germany
  • Rostock, Germany
  • Saarbrucken, Germany
  • Schorndorf, Germany
  • Research Site
    Singen, Germany
  • Speyer, Germany
  • Stade, Germany
  • Stolberg, Germany
  • Stuttgart, Germany
  • Traunstein, Germany
  • Research Site
    Ulm, Germany
  • Villingen-Schwenningen, Germany
  • Westerstede, Germany
  • Research Site
    Wilhelmshaven, Germany
  • Witten, Germany
  • Würselen, Germany
  • Würzburg, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Feb 2023, 77 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 77 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2016
First posted
Sep 9, 2016
StartActual
Sep 6, 2016
Primary completionActual
Feb 15, 2023
CompletionActual
Feb 15, 2023
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02894398
Lead sponsor
iOMEDICO AG
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Sep 9, 2016
Start date
Sep 6, 2016
Primary completion
Feb 15, 2023
Completion
Feb 15, 2023
Last update
Mar 13, 2023

Study contacts

iOMEDICO AG
study chair · Freiburg / Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion